Zusammenfassung
Die Polyneuropathie bei Patientinnen und Patienten mit onkologischen Erkrankungen kann als paraneoplastisches Syndrom sowie infolge einer Tumorbehandlung auftreten.
Die Untersuchungen im Rahmen der Diagnostik der Polyneuropathie bei Patientinnen und Patienten mit einer onkologischen Erkrankung bestehen aus Anamnese, klinischer Untersuchung (inkl. neurologischem Status), Laboruntersuchungen, elektrophysiologischer Untersuchung und Quantitative Sensory Testing. Fakultative Untersuchungen (je nach Differenzialdiagnose) sind die Lumbalpunktion, die Biopsie (Muskel-, Nerv- oder Hautbiopsie) und genetische Untersuchungen.
Die Therapie der Polyneuropathie bei Patientinnen und Patienten mit onkologischen Erkrankungen erfolgt interdisziplinär und multiprofessionell und besteht aus einer multimodalen Therapie. Hier ist die Kombination aus medikamentöser Therapie und physikalischen Therapien zu nennen.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Abraham A, Alabdali M, Alsulaiman A (2017) The sensitivity and specificity of the neurological examination in polyneuropathy patients with clinical and electrophysiological correlations. PLoS One 12(3):e0171597
Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113–3120
Antoine PJC, Camdessanché JP (2017) Paraneoplastic neuropathies. Curr Opin Neurol 30(5):513–520
Argyriou AA, Cavaletti G, Briani C (2013) Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer 119:438–444
Azhary H, Farooq MU, Bhanushali M, Majid A, Kassab MY (2010) Peripheral neuropathy: differential diagnosis and management. Am Fam Physician 81(7):887–892
Bruna J, Udina E, Ale A (2010) Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Exp Neurol 223(2):599–608
Cavaletti G, Tredici G (2009) Role of MAPKs in platinum-induced neuronal apoptosis. Neurotoxicology 30:312–319
Cavaletti G, Cavalletti E, Montaguti P, Oggioni N, De Negri O, Tredici G (1997) Effect on the peripheral nervous system of the shortterm intravenous administration of paclitaxel in the rat. Neurotoxicology 18:137–145
Chu SH, Lee YJ, Lee ES, Geng Y, Wang XS, Cleeland CS (2015) Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review. Support Care Cancer 23(2):513–524
Cocito D, Romagnolo A, Rosso M, Peci E, Lopiano L, Merola A (2015) CIDP-like neuropathies in graft versus host disease. J Peripher Nerv Syst 20(1):1–6
Crevenna R (2017) Kompendium Physikalische Medizin und Rehabilitation. Diagnostische und therapeutische Konzepte. Springer, Berlin/Heidelberg
Crevenna R, Ashbury FD (2018) Physical interventions for patients suffering from chemotherapy-induced polyneuropathy. Support Care Cancer 26(4):1017–1018
De Wit R, Roberts JT, Wilkinson PM et al (2001) Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19:1629–1640
El-Kareh AW, Labes RE, Secomb TW (2008) Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drugs. AAPS J 10:15–34
EORTC (1995) Quality of life group. Version 3.0. http://www.eortc.org/app/uploads/sites/2/2018/08/Specimen-QLQ-C30-English.pdf. Zugegriffen am 29.11.2018
Fehmi J, Scherer SS, Willison HJ, Rinaldi S (2018) Nodes, paranodes and neuropathies. J Neurol Neurosurg Psychiatry 89(1):61–71
Ferreira-Valente MA, Pais-Ribeiro JL, Jensen MP (2011) Validity of four pain intensity rating scales. Pain 152:2399–2404
Freynhagen R, Baron R, Gockel U, Tölle TR (2006) painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 22(10):1911–1920
Gertz MA (2014) Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. Am J Hematol 89(12):1132–1140
Gill JS, Windebank AJ (1998) Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest 101:2842–2850
Grisold W, Grisold A, Löscher WN (2016) Neuromuscular complications in cancer. J Neurol Sci 367:184–202
Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E (2001) A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85:2293–2297
Joseph EK, Chen X, Bogen O, Levine JD (2008) Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. J Pain 9:463–472
Khan F, Amatya B (2012) Rehabilitation interventions in patients with acute demyelinating inflammatory polyneuropathy: a systematic review. Eur J Phys Rehabil Med 48(3):507–522
Klinke R, Silbernagel S (1996) Lehrbuch der Physiologie, 2. Aufl. Georg Thieme, Stuttgart/New York
Koeppen S (2007) Management der therapiebedingten Neurotoxizität. Taube Stellen, kribbelnde Finger – Nervenschäden gezielt vermeiden. Im Focus Onkologie 11:64–70
Krishnan AV, Goldstein D, Friedlander M, Kiernan MC (2005) Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 32:51–60
Lauria G, Hsieh ST, Johansson O et al (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 17:903–912
Leitlinienprogramm Onkologie (2017) Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF. Supportive Therapie bei onkologischen PatientInnen– Langversion. http://www.awmf.org/uploads/tx_szleitlinien/032-054OLl_S3_Supportiv_2017-05.pdf. Zugegriffen am 29.11.2018
Manna A, Sarkar SK, Khanra LK (2015) PA1 – An internal audit into the adequacy of pain assessment in a hospice setting. BMJ Support Palliat Care 5(Suppl 1):A19–A20
Mauermann ML (2018) The peripheral neuropathies of POEMS syndrome and castleman disease. Hematol Oncol Clin North Am 32(1):153–163
Mendell J, Kissel J, Cornblath D (2001) Diagnosis and management of peripheral nerve disorders. Oxford University Press, Oxford
Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM (2006) Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 24:4507–4514
Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohty M (2010) Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica 95:311–319
Morawska M, Grzasko N, Kostyra M, Wojciechowicz J, Hus M (2015) Therapy-related peripheral neuropathy in multiple myeloma patients. Hematol Oncol 33(4):113–119
Müller K, Meineke V (2011) Radiation induced mast cell mediators differentially modulate chemokine release from dermal fibroblasts. J Dermatol Sci 61(3):199–205
Neundörfer B, Heuß D (2006) Toxische Polyneuropathien. Thieme, Stuttgart, S 61–77
Nicolini G, Monfrini M, Scuteri A (2015) Axonal transport impairment in chemotherapy-induced peripheral neuropathy. Toxics 3:322–341
Ocean AJ, Vahdat LT (2004) Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 12:619–625
Park SB, Lin CS-Y, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC (2011) Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy. Exp Neurol 227:120–127
Pasetto LM, D’Andrea MR, Rossi E, Monfardini S (2006) Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol 59:159–168
Persohn E, Canta A, Schoepfer S (2005) Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer 41:1460–1466
Pietrangeli A, Milella M, DeMarco S et al (2000) Brachial plexus neuropathy as unusual onset of diffuse neurolymphomatosis. Neurol Sci 21:241–245
Podratz JL, Knight AM, Ta LE (2011) Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol Dis 41(3):661–668
Richardson PG, Xie W, Mitsiades C (2009) Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 27:3518–3525
Rolke R, Baron R, Maier C (2006) Quantitative sensory testing in the German research network on neuropathic pain (DFNS): standardized protocol and reference values. Pain 123(3):231–243
Schmincke C (2017) Ein Blick in die Anatomie des peripheren Nervensystems. In: Ratgeber Polyneuropathie und Restless Legs. Springer, Berlin/Heidelberg
Shin SC, Robinson-Papp J (2012) Amyloid neuropathies. Mt Sinai J Med 79(6):733–748
Steimann M (2014) Chemotherapieinduzierte Polyneuropathie: Grundlagen, Diagnostik und Prävention. GMS Onkol Rehabil Sozialmed 3:Doc05. https://doi.org/10.3205/ors000013. URN: urn:nbn:de:0183-ors0000139
Treede RD, Jensen TS, Campbell JN et al (2008) Neuropathic pain: redefinition and a grading system for clinical and research purposes Neurology. Neurology 70:1630–1635
Vass A, Grishold W (2009) Chemotherapie-induzierte Neuropathien (CIN). J Neurol Neurochir Psychi 10(2):44–47
Verstappen CCP, Koeppen S, Heimans JJ et al (2005) Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 64:1076–1077
Vliagoftis H, Befus AD (2005) Rapidly changing perspectives about mast cells at mucosal surfaces. Immunol Rev 206:190–203
Walsh LJ (2003) Mast cells and oral inflammation. Crit Rev Oral Biol Med 14(3):188–198
Wang MS, Wu Y, Culver DG, Glass JD (2000) Pathogenesis of axonal degeneration: parallels between Wallerian degeneration and vincristine neuropathy. J Neuropathol Exp Neurol 59:599–606
WHO (2001) . https://www.who.int/classifications/icf/en/. Zugegriffen am: 3.9.2019
Zedan AH, Vilholm OJ (2014) Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires. Basic Clin Pharmacol Toxicol 115(2):193–200
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Keilani, M., Sycha, T., Licht, T., Crevenna, R. (2020). Polyneuropathie bei Patienten mit onkologischen Erkrankungen. In: Crevenna, R. (eds) Onkologische Rehabilitation. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57982-4_8
Download citation
DOI: https://doi.org/10.1007/978-3-662-57982-4_8
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-57981-7
Online ISBN: 978-3-662-57982-4
eBook Packages: Medicine (German Language)